Immucell Stock Price, News & Analysis

ImmuCell (Nasdaq: ICCC) will announce its unaudited financial results for the quarter ended June 30, 2024, after market close on Tuesday, August 13, 2024. A conference call is scheduled for Wednesday, August 14, 2024, at 9:00 AM ET to review these results. Access the call at (844) 855-9502 (toll-free) or (412) 317-5499 (international). A replay is available until August 21, 2024, at (877) 344-7529 (toll-free) or (412) 317-0088 (international), using access code #3744296.

The Company expects no changes to the preliminary sales results disclosed on July 9, 2024. The Quarterly Report on Form 10-Q will be filed after market close on August 13, 2024. Investors are encouraged to review the updated Corporate Presentation slide deck on the Company's website post-announcement.

ImmuCell (Nasdaq: ICCC) has announced preliminary, unaudited sales results for Q2 2024. The company reported a 55% increase in sales to $5.47 million for the three-month period ended June 30, 2024, compared to $3.53 million in the same period of 2023. For the first half of 2024, sales rose by 82% to $12.73 million, and for the twelve-month period, sales increased by 48% to $23.22 million. The company's production output was between 74% and 85% of its full capacity. Additionally, ImmuCell is working towards FDA approval for Re-Tain®, with submission expected after resolving inspectional observations. A conference call is scheduled for August 14, 2024, to discuss these results further.

ImmuCell provided an update on the regulatory status of its product development initiative for Re-Tain®. The company received a Technical Section Incomplete Letter from the FDA for its third submission of the CMC Technical Section, important for its NADA. ImmuCell has prepared a fourth submission but must clear inspectional observations at its facilities before submitting. The FDA confirmed acceptable inspectional status for ImmuCell, and its contract manufacturer expects to respond to inspectional observations by end of June 2024. The company anticipates a Non-Administrative NADA submission, possibly subject to a shorter review period, aiming for FDA approval and a controlled launch strategy between Q2 2025 and Q1 2026.

ImmuCell (Nasdaq: ICCC) has announced that its 2024 Annual Meeting of Stockholders will be held virtually on June 13, 2024, at 9:30 AM ET. The meeting will be conducted via telephone conference call and live audio webcast, not in person. Stockholders of record as of April 15, 2024, can participate by dialing specific toll-free numbers or accessing the webcast. Participation in the Q&A session post-meeting will be to the telephone call. A replay will be available until June 19, 2024. Stockholders are encouraged to vote in advance via proxy. More information is available on the company's website and SEC filings.

ImmuCell (Nasdaq: ICCC) reported a significant 111% year-over-year increase in product sales for Q1 2024, totaling $7.3 million. This marks the highest quarterly sales in the company's history. The trailing twelve-month sales also rose by 33%, reaching $21.3 million. Gross margin improved to 32%, up from 9% in Q1 2023. Despite these gains, the company reported a net loss of $438,000, a substantial improvement from the $2.3 million loss in the same period last year. EBITDA turned positive at $377,000 from a negative $1.6 million in Q1 2023. A backlog of $9.1 million in orders remains. However, cash reserves decreased slightly to $960,000. The FDA has delayed the approval of ImmuCell's Re-Tain® product due to pending inspectional observations at their contract manufacturer.

ImmuCell (Nasdaq: ICCC) will announce unaudited financial results for the quarter ended March 31, 2024 on May 14, 2024. The conference call to review the results is scheduled for May 15, 2024. Interested parties can access the call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET. The Company expects no change to the preliminary sales results disclosed on April 9, 2024. Investors can review the updated Corporate Presentation slide deck on the Company's website.